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Abstract
Lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery disease (CAD) are expected to cause most 
deaths by 2050. State-of-the-art computed tomography (CT) allows early detection of lung cancer and simultaneous evalua-
tion of imaging biomarkers for the early stages of COPD, based on pulmonary density and bronchial wall thickness, and of 
CAD, based on the coronary artery calcium score (CACS), at low radiation dose. To determine cut-off values for positive 
tests for elevated risk and presence of disease is one of the major tasks before considering implementation of CT screening 
in a general population. The ImaLife (Imaging in Lifelines) study, embedded in the Lifelines study, is designed to establish 
the reference values of the imaging biomarkers for the big three diseases in a well-defined general population aged 45 years 
and older. In total, 12,000 participants will undergo CACS and chest acquisitions with latest CT technology. The estimated 
percentage of individuals with lung nodules needing further workup is around 1–2%. Given the around 10% prevalence of 
COPD and CAD in the general population, the expected number of COPD and CAD is around 1000 each. So far, nearly 
4000 participants have been included. The ImaLife study will allow differentiation between normal aging of the pulmonary 
and cardiovascular system and early stages of the big three diseases based on low-dose CT imaging. This information can 
be finally integrated into personalized precision health strategies in the general population.
Keywords Cardiovascular disease · Chronic obstructive pulmonary disease · General population · Imaging biomarkers · 
Low-dose computed tomography · Lung cancer
Rationale
Lung cancer, chronic obstructive pulmonary disease (COPD) 
and coronary artery disease (CAD) are in the top ten global 
causes of death [1]. In this top ten, over three-quarters of 
individuals dying of non-communicable diseases, succumb 
to one of these three diseases, sometimes called the ‘big-3’ 
(B3).
Early detection of B3 diseases by low-dose computed 
tomography (CT) could provide opportunities for early treat-
ment and possibly reduce mortality in the overall population. 
Lung cancer screening using low-dose chest CT is now rec-
ommended to detect early cases of lung cancer [2]. Quan-
tification of CT imaging biomarkers such as lung density 
and bronchial wall thickness may allow early detection of 
COPD [3, 4]. As low-dose chest CT for lung cancer screen-
ing inherently includes the heart in its field of view, this 
has the potential for the evaluation of CAD as well. Efforts 
are underway to develop a CT scan protocol that will allow 
accurate evaluation of B3 imaging biomarkers with one 
image acquisition [5].
Although B3 diseases share certain risk factors (aging 
and smoking) and mechanisms (systematic inflammation and 
endothelial dysfunction), there are also important differences 
in risk factors between lung and heart diseases that can affect 
screening recommendations. Current lung cancer screening 
recommendations focus on high-risk, long-term smokers. 
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For COPD and CAD, at this moment no at-risk groups are 
defined that may benefit from screening. Excellent large-
scale imaging studies have been performed aimed at investi-
gating one of the B3 diseases (see Table 1). The lung cancer 
imaging studies have been interventional screening studies 
in a high-risk population, while studies on CAD and COPD 
have generally been observational in design, and for CAD 
often included a more general population. A smaller num-
ber of studies included evaluation of a second B3 disease, 
often based on the same CT scan (which is suboptimal for 
evaluation of the other B3 disease), or by performing an 
additional dedicated CT scan, usually in a subset. There is so 
far no population imaging study that is focused on obtaining 
the B3 imaging biomarkers in a comprehensive, integrated 
approach with an optimized CT scan protocol. In view of 
the different risk factors for individual B3 diseases, it is not 
unreasonable to contemplate the possibility of B3 screening 
in the general adult population, or in an optimized selection 
Table 1  Large-scale studies with evaluation of at least two of the big three diseases based on (semi-)quantitative imaging biomarkers
√, coronary calcium scoring as a imaging biomarker for CVD; ‡, Lung density (i.e., emphysema, air trapping) and airway wall thickness as 
imaging biomarkers for COPD; †, Lung density based imaging biomarker for emphysema; ○, volume (volume doubling time) of lung nodules as 
imaging biomarkers for early stage of lung cancer; × , diameter of lung nodules as imaging biomarkers for early stage of lung cancer
COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, CACS coronary artery calcium score, SCAPIS Swedish CArdioPul-
monarybioImage Study, NELSON Dutch-Belgian Lung Cancer Screening trial, NLST National lung cancer screening trial, MILD Multi-centric 
Italian Lung Detection, I-ELCAP international early lung cancer action program, DLST Danish lung cancer screening trial, PLuSS Pittsburgh 
Lung Screening Study, ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points, GOLD global initiative for 





Age (years) Primarily aimed at Ancillary studies aimed at (sample size)
Lung cancer COPD CVD Lung cancer COPD CVD
SCAPIS [46] General popula-
tion





15,822 50–75 ○ ‡ (1,140) √ (3,111)




53,454 55–74 × ‡ (558) √ (1,575)
MILD [36, 39] Heavy (ex-)
smokers
4099 ≥ 49 ○ † (1,159) √ (1,159)
I-ELCAP [34, 
40, 48]










3206 55–69 × † (266)
DLCST [35, 41] Heavy (ex-)
smokers
4104 50–70 × √ (1,945)
PLuSS [51, 52] Heavy (ex-)
smokers











with at least 
10 pack-years 




45–80 ‡ √ (1,875)
MESA [16, 44] Free of apparent 
cardiovascular 
disease











Men ≥ 35; 
women ≥ 40
√ ‡ (nearly 3000)
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of the population based on (combinations of) risk factors for 
premature development of B3 diseases.
ImaLife is the first large-scale imaging study focusing on 
combined evaluation of early imaging biomarkers of the B3. 
In the ImaLife study, a low-dose CT scan is acquired with 
dedicated protocol for cardiac and lung imaging biomark-
ers. With help of these data, we will determine reference 
values of early imaging biomarkers of the B3 in the general 
adult population. This will allow differentiation between 
normal ageing and premature development of subclinical 
B3 diseases by age and gender. Instead of treating these as 
three independent diseases, a B3 concept to manage these 
degenerative diseases holistically might be more effective 
[6]. In ImaLife, inter-relatedness between early stages of B3 
diseases will be investigated. Furthermore, these data will 
help to define an at-risk population that could benefit from 
screening for B3 diseases.
Objectives
The primary objective of ImaLife study is to establish CT 
reference values of quantitative imaging markers for the 
B3 diseases in the general population aged 45 years and 
older, namely lung nodules for lung cancer, lung density and 
bronchial wall thickness for COPD, and CACS for CAD. 
As the ImaLife study is embedded in the Lifelines cohort, 
a large prospective cohort with extensive data collection in 
the north of the Netherlands [7], the study will also allow 
the (1) analysis of correlations of imaging biomarkers to 
lifestyle factors, demographic characteristics, environmental 
factors, and other clinical biomarkers including conventional 
laboratory biomarkers, metabolic biomarkers and so forth, 
(2) investigation of the inter-relationship between early 
stages of B3, (3) identification of at-risk subgroups in the 
population for premature development of the B3, (4) valida-
tion of the value of early imaging biomarkers for predicting 
clinical stages of the B3 diseases, and (5) investigation of 




The National Lung Screening Trial (NLST) showed the 
benefit of low-dose CT to reduce lung cancer mortality in 
at-risk individuals [8]. However, there was a high false-
positive rate due to the single measurement of a nodule 
diameter for determining screen result. The key to reduce 
false-positive rates may be found in using semi-automated 
volumetric nodule quantification and calculating volume 
doubling time (VDT) of indeterminate lung nodules [2]. 
The Dutch-Belgian lung cancer screening trial (NELSON) 
provided evidence that volume-based CT screening is an 
effective method of lung cancer screening, with much lower 
false positives [9, 10]. Reference values of nodule volume 
and VDT are important, especially when aiming to prevent 
unnecessary follow-up CT scans and unnecessary fear of 
cancer. While lung cancer screening studies focused on high-
risk long-term smokers, little is known about the prevalence 
and size and growth of lung nodules in a general population.
The coronary artery calcium score (CACS) is the strong-
est non-invasive predictor for coronary events [11–16], and 
its impact as screening tool is currently under investigation 
[17]. Previously, the Heinz Nixdorf Recall (HNR) study 
[15] and the Multi-Ethnic Study of Atherosclerosis (MESA) 
[16] provided the distribution of CACS in unselected adult 
populations without clinical CVD in Germany, and USA 
respectively. The Rotterdam study evaluated the CACS in 
the older population [18]. Apart from MESA, these studies 
only focused on CAD, without relating CACS to other B3 
diseases.
Early stages of COPD can be quantified by measuring 
emphysema, bronchial wall thickness and air trapping on 
chest CT scans [19]. Structural lung abnormalities on CT 
were found to increase the risk of lung cancer and mortal-
ity [20–22]. Presence and severity of COPD imaging bio-
markers in the general population are largely unknown. In a 
subset of MESA, the cardiac CT scan was used to determine 
some estimate of COPD measures, however, the higher lung 
fields, where emphysema typically starts, were not imaged.
Lifelines
The Lifelines study is a longitudinal cohort study and 
biobank in a large three-generation population in the 
northern part of the Netherlands, comprising over 167,000 
participants [7, 23]. The Lifelines cohort study has been 
established in 2006. Baseline assessments were completed 
in 2013, after which second-round assessments have been 
started and completed in 2017. The third-round assessments 
will start in 2019. Participants are invited to complete a 
physical examination with lab testing once every assessment 
round, and questionnaires once (on average) every 1.5 years. 
Not only medical information but also environmental data 
are collected to investigate the complex interaction between 
possible risk factors, chronic diseases, and healthy aging. 
More details about specific variables that collected in the 
Lifelines biobank can be found at [www.lifel ines.nl]. Life-
lines has regular examination rounds, in which participants, 
amongst other exams, fill in questionnaires. The question-
naire includes questions about health status, and the occur-
rence and prevalence of disease such as lung cancer or CAD. 
This is the primary way in which information regarding 
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incidence of B3 diseases is obtained within Lifelines [7]. 
Also, Lifelines is working to create a link with GP data, in 
order to obtain clinical diagnoses of the participants. From 
the Lifelines cohort, 12,000 participants aged 45 years and 
above are invited for the ImaLife substudy (expected age 
range 45–94 years, and at least 50% women).
ImaLife study population and recruitment strategies
The ImaLife substudy is an imaging study with state-of-
the-art CT scanning procedures embedded in Lifelines. 
For an overview of the study, see Fig. 1. The ImaLife 
study includes Lifelines participants who completed the 
second round assessment of the Lifelines study, and as 
part of the second round assessment, completed a lung 
function test. The cohort invited for lung function test-
ing was unselected (primarily based on scheduling of 
lung function test slots). However, there was a number 
of exclusion criteria for lung function testing, related to 
conditions in which intrathoracic pressure increase need 
to be prevented, namely: (1) known abdominal hernia 
(including inguinal, umbilical, incisional), rib fracture, 
aneurysm, or tuberculosis, (2) recent cardiac catheteriza-
tion (within 2 weeks prior), (3) recent respiratory infec-
tion (within 3 weeks prior), (4) recent (within 6 weeks) 
surgery for abdominal hernia, ocular surgery, thoracic or 
abdominal surgery, (5) recent (within 6 weeks) pneumo-
thorax or more than 2 times spontaneous pneumothorax, 
(6) recent (within 2–6 weeks) pulmonary embolism, (7) 
recent (within 2–6 weeks) myocardial infarction, (8) indi-
cation by general practitioner or medical specialist that no 
(heavy) exercise was to be performed. Also, participants 
who were unable to complete the lung function test due 
to dizziness or hyperventilation were excluded. In total, 
32,113 Lifelines participants completed the lung function 
test (age range 18–94 years, 58.8% female). Of these, all 
Lifelines individuals aged 45 years and above are invited 
for the ImaLife study (n = 22,000).
Fig. 1  Overview of the ImaLife study. CT computed tomography, COPD chronic obstructive pulmonary disease, CAD coronary artery disease, 
GPs general practitioners, ID identification number
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A cut-off of age 45 years is chosen because early B3 
stages, as well as positive imaging biomarkers for lung nod-
ules, COPD and CAD are rare below 45 years [24–26]. This 
lower cut-off is similar to other large-scale imaging stud-
ies (see Table 1). Even though f.e. coronary calcium is less 
prevalent in women than in men, it is important to have the 
same lower age cut-off to be able to compare early B3 imag-
ing biomarkers in terms of presence and extent for men and 
women at the same age.
Participants who are invited to participate in the ImaLife 
study receive an invitation letter, an information brochure 
about the ImaLife study including discussion of possible 
risks and benefits, an informed consent form and an avail-
ability form. Participants who return the signed informed 
consent will be included in the ImaLife study. We exclude 
pregnant women and individuals who underwent chest CT in 
the past year. The latter because of the probability of existing 
clinically potential life-limiting B3 disease. Subsequently, 
participants receive an appointment to undergo the CT scan 
from the Lifelines organization. With an expected positive 
response rate for the invitation 50–60%, the total number of 
participants for the ImaLife study will be around 12,000. For 
the primary objective, outcomes will be obtained for all par-
ticipants, namely quantitative imaging biomarkers on lung 
nodules, lung density, bronchial wall thickness, and CACS. 
This allows determination of reference values of the imaging 
biomarkers of early stages the B3 in this general population 
by gender and 5 or 10-year age groups.
Image acquisition and analysis
Study participants undergo a low dose chest CT examination 
with third-generation dual-source CT (SOMATOM Force, 
Siemens, Germany). First a CACS acquisition with electro-
cardiography (ECG) triggering is performed, followed by a 
low dose chest CT acquisition. The protocol of cardiac CT is 
based on the acquired experience of the ROBINSCA study 
[17], while the protocol of low-dose thoracic CT is modified 
from the low-dose CT protocol in the NELSON study [27]. 
Both are adapted to the latest generation dual-source CT sys-
tem. In addition, a subset of 100 participants for each 5-year 
age/gender category (in total, about 1000 participants) will 
undergo an additional acquisition with end-expiratory breath 
hold, in order to determine normal values for expiratory 
lung density and air trapping. Details of the acquisition and 
reconstruction parameters are presented in Tables 2 and 3. 
Radiologic technologists who are trained in the low-dose CT 
scan protocol are responsible for CT scanning.
Syngo.via software (version VB30) with MM Oncology 
application (Siemens Healthineers, Germany) will be used 
for lung analysis and volumetric quantification of lung nod-
ules. If a non-calcified lung nodule is found (100–300 mm3), 
the participant is invited for a repeat low-dose CT scan of the 
lungs in inspiration after 3 to 4 months to study the persis-
tence of nodules, and reference values of VDT in the general 
population. The VDT will be determined basing on the for-
mula as previously reported [28].
Table 2  CT scanning protocol 
for coronary artery calcium 
score and lung scan
a The pitch is set as 3.0 for lung scans with a field of view 350 mm for reconstruction, while the pitch will 
be modified to 2.5 with a field of view enlarged to 400 mm for reconstruction in participants with larger 
body sizes
b A subset of 100 participants per 5-year age/gender category will undergo an additional acquisition with 
end-expiratory breath hold
CT computed tomography, CACS coronary artery calcium score, ECG electrocardiography, API automated 
patient instruction
Acquisition parameters CT protocol
CACS Lung
Scan mode High pitch spiral High pitch spiral
Pitch 3.2 3.0/2.5a
Tube voltage (kVp) 120 120
Tube current reference (ref mAs) 64 20
Rotation time (ms) 250
Matrix 512 × 512
ECG triggering Yes, prospective at 60% of the R–R 
interval
No
Dose modulation Care-kV off Care-kV off
API Inspiratory breath-hold Inspiratory/expira-
tory breath-holdb
Direction Craniocaudal
Upper limit Below carina Above lung apex
Lower limit Apex/bottom edge heart Caudal edge lungs
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Evaluation of COPD will be performed on low dose 
chest CT scans with inspiratory and expiratory breath 
hold Bronchial wall thickness and pulmonary volume and 
density will be analyzed using semi-automated software 
(Pulmo3D, Siemens Healthineers, and others).
Coronary calcification will be evaluated using semi-
automated CACS software (CaSc, Siemens Healthineers, 
Germany). Agatston score, volume score and mass score 
will be archived, overall and per artery. Although coronary 
calcification is a predictor for cardiovascular disease [11, 
13, 14], there is no clinical evidence that early interven-
tion in case of higher burden of coronary calcification can 
reduce cardiovascular risk or improve clinical outcomes 
so far. Therefore, in view of ethical considerations in the 
context of ImaLife being an observational population 
study, the result of CACS will not be reported to study 
participants and GPs.
Reading of the scans is performed by and/or under the 
supervision of radiologists (6–12 years of experience in 
cardiothoracic imaging). Researchers with a background 
in (technical) medicine perform the measurements of lung 
nodule volumes, COPD imaging biomarkers, and calcium 
scoring, after adequate training (educational dataset of at 
least 50 cases for lung nodules and 50 cases for calcium 
scoring, with feedback on trainee evaluations).
Notification of incidental findings
ImaLife is in principle an observational study. In accordance 
with the observational nature of the study, information on 
early imaging biomarkers of COPD or coronary calcium, 
and lung nodules with small volume, is not reported to the 
participants. B3 imaging biomarkers are considered early 
imaging biomarkers of subclinical disease that may or may 
not lead to clinical expression in the future. Only an inciden-
tally detected, potentially life-shortening and thus clinically 
relevant finding will be reported to the participant and his/
her GP. This finding may require further management if it 
was not previously known. In case the radiologist notices a 
potentially clinically relevant finding while reviewing the 
lung scan, he/she will report this in the digital notification 
system to Lifelines. The findings that are reported if inci-
dentally detected, are listed in Table 4. In such cases, the 
GP will be the first to receive the information regarding the 
Table 3  CT reconstruction protocols for coronary artery calcium score and lung scan
CACS coronary artery calcium score, FOV field of view, FBP filtered back projection, HU hounsfield units
Reconstruction parameters CACS Lung
Reconstruction Reconstruction 1 Reconstruction 2 Reconstruction 3
Slice thickness (mm) 3.0 1.0 1.0 1.0
Slice increment (mm) 1.5 0.7 0.7 0.7
FOV (mm) 250 350 (400 if 350 too small) 350 (400 if 350 too small) 350 (400 if 350 too small)
Reconstruction kernel Qr36 (Quantitative-
medium sharp)
Bl57 (Qualitative-sharp) QR59 (Quantitative-sharp) Br40 (Qualitative-smooth)
Reconstruction method FBP FBP FBP FBP
Window Mediastinum Lung Lung Mediastinum
Window width (HU) 350 1600 1600 350
Window center (HU) 50 − 400 − 400 50
Table 4  Incidental findings on the low-dose CT scan that are and that are not reported to participant and GP, if accidentally detected
VDT volume doubling time
Reported Not reported
Chest Aortic aneurysm ≥ 50 mm Valve calcification (aortic, mitral, etc.)
Calcified pleural plaques ≥ 1 cm thickness Annulus calcification
Pleural fluid ≥ 2 cm thickness Pericardial abnormalities (thickening, 
calcification, etc.)
Lung nodule with size ≥ 300 mm3 (0.8 cm) or fast growing (VDT < 400 days) if 
100–300 mm3 (0.6-0.8 cm)
Hiatal hernia
Identifiable thoracic mass (> 3 cm)
Abdomen Very large liver cyst(s) (> 10 cm) Small to medium size liver cyst(s)
Identifiable abdominal mass (> 3 cm)
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potentially clinically relevant finding. Results regarding inci-
dental findings are in principle available within 10 working 
days after the CT scan and sent to the GP. Participants will 
receive a letter within 10 working days after the GP receives 
the result. The participant is advised to contact the GP for 
more information and referral to a medical specialist, if the 
incidental finding was not previously known. Taking the 
medical history into account, the GP will make the final 
decision to refer the participant to a medical specialist to 
further investigate the finding. The medical specialist can 
request a DVD with the (anonymized) CT scan. One of the 
incidental findings that is reported to participant and GP, is 
a lung nodule of at least 300 mm3, according to published 
recommendations [2], as it cannot be ruled out that a nodule 
with this volume is an early stage of pulmonary malignancy 
that is assumed to inevitably result in clinical expression. 
Incidental findings without evident potential clinical rele-
vance will not be reported in view of ethical considerations 
in this non-screening, observational study in the general 
population.
Radiation dose management
With the use of third-generation dual-source CT and modi-
fied scan protocols, the effective radiation dose for par-
ticipants undergoing a baseline ImaLife CT scan will be 
between 0.6 and 1.8 mSv, depending on weight and length. 
Additionally, the subset of participants who undergo an 
expiratory breath hold scan, will receive an extra 0.1 to 
1.3 mSv. In case of a follow-up scan (nodule 100–300 mm3, 
expected in 5–10% of participants), the repeat thorax CT 
scan in three to four months will result in an additional 
0.8 mSv on average. To put these estimates into perspective, 
the natural background radiation dose in the Netherland is 
about 2.5 mSv per year [29]. These dose ranges fit within the 
radiation dose limits for population imaging as described by 
the Dutch Health Council [30]. The CT system will provide 
a dose warning when the projected radiation dose for the CT 
scan will exceed the upper dose limit based on dose-length 
product. The overall radiation dose will be checked at regu-
lar intervals in order to check the actual radiation dose in the 
scanned population.
Data storage and management
Participants are invited by Lifelines and are linked to a new 
ImaLife participant identification number (ID) that is unre-
lated to their Lifelines participant ID. The CT scanning and 
scan evaluation is performed using this specific ImaLife 
participant ID. Only Lifelines has the key to link pseudon-
ymous imaging biomarkers to the Lifelines database. By 
this method, the researchers involved in ImaLife who are 
performing the data evaluation have no link whatsoever to 
the real identity of the participant. This identity can only be 
retrieved by Lifelines, which is why communication to the 
participants or their GP is done by Lifelines. In this setup, 
Lifelines is acting as a Trusted Third Party thus achiev-
ing optimal protection of the privacy of the participants. 
Pseudonymous scans will be uploaded to a secure virtual 
research workspace which allows access to imaging software 
for analyses, connection with research Picture Archiving and 
Communication System (PACS), and linkage to data storage. 
Image analyses will be conducted by the trained researchers 
and radiologists via the ENACT workspace. Registration 
of all measurement results is made in a dedicated ImaLife 
data management system. Only validated imaging markers 
derived from the quantitative image analyses will be added 
to the Lifelines database.
Statistical considerations
The percentage of women in Lifelines is relatively high 
(58.5% versus 50.7% in the entire population of the Northern 
Netherlands) [23]. In the Lifelines cohort, there is a suffi-
cient prevalence of ever smoking and (other) cardiovascular 
risk factors, with more than 70% of participants having at 
least one traditional cardiovascular risk factor [31].
Within the B3, COPD and CAD are most common with 
10% prevalence including early stages in the adult popula-
tion. The expected number of individuals with early stages 
of COPD and CAD is at least 1000 each, allowing detailed 
analyses of the research questions. The study is calculated 
to have more than 95% power to identify the relationship 
between risk factors with a prevalence of at least 10% in the 
ImaLife cohort and presence of coronary calcium with an 
odds ratio of 1.3 or greater, and presence of COPD with an 
odds ratio of 1.5 or greater, given an alpha error of 5%. It is 
expected that there will be approximately 900 CVD events 
and 300 COPD events occurring in a 5 year period, given 
the incidence rate of CVD and COPD of nearly 15 and 5 per 
1000 per year, respectively [32, 33], allowing the analyses of 
the relationship between imaging biomarkers and outcomes. 
The prevalence of (early) lung cancer in the general popula-
tion above 45 years is low, although lung nodules are com-
mon (about 50% in (ex-) smokers, based on the NELSON 
study, and 2.6% with a positive screen test [27]). The preva-
lence of current smoking in Lifelines is about 25%, which is 
lower compared to the NELSON study. We hereby estimate 
that there will be about 120–240 individuals (1–2%) with a 
positive test that need referral to a pulmonologist and further 
work-up. This is adequate to answer the research questions 
for the whole population, but insufficient to perform analyses 
in subgroups of gender, age, and environmental exposure.
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Ethical considerations and privacy issues
The ImaLife study was approved by the medical ethics 
committee of the University Medical Center Groningen, 
the Netherlands. All participants sign an informed con-
sent form prior to the investigational procedures; informed 
consent forms are stored at the Lifelines organization. 
The ImaLife study was registered with the Dutch Central 
Committee on Research Involving Human Subjects (https 
://www.toets ingon line.nl, Identifier:NL58592.042.16). By 
implementing a twofold de-identification process decoupling 
the identity of the participant completely from the ImaLife 
ID, we are complying with the rules and regulations con-
cerning the protection of privacy (General Data Protection 
Regulation—GDPR).
Discussion
The ImaLife study will establish reference values of early 
imaging biomarkers for the B3 diseases, namely, lung nod-
ules (volume and VDT), bronchial wall thickness, pulmo-
nary density, and CACS in the general population in the 
northern part of the Netherlands aged 45 years and above. 
These reference values can be used in the future to determine 
premature, subclinical development of B3 diseases, and for 
modeling personalized prevention strategies in the general 
population.
To the best of our knowledge, the ImaLife study is the 
first population-based imaging study aiming to detect the 
early stages of the B3 diseases and to establish reference 
values for the B3 imaging biomarkers. Previous studies were 
primarily aimed at one or two of the B3 diseases, gener-
ally in a selected population (summarized in Table 1). For 
instance, lung cancer screening trials including NELSON, 
NLST, MILD, I-ELCAP, DLCST were originally designed 
to show whether screening of lung cancer in targeted-popu-
lation with low-dose chest CT could reduce mortality [8, 27, 
34–36]. But CACS based on the non-ECG-triggered chest 
CT was reviewed later as an ancillary study to investigate 
the predictive value of CACS for cardiovascular events, due 
to the visibility of the heart on regular chest CT [37–41]. 
The same goes for the ECLIPSE study and the COPDGene 
study which were primarily designed for COPD evaluation 
[42, 43]. Vice versa, the MESA study, which was originally 
established for subclinical cardiovascular disease and risk 
factors assessment, was expanded with a lung scan acquisi-
tion to test the endothelial hypothesis of COPD and emphy-
sema [44]. Compared with these large population studies 
with imaging, the ImaLife study is originally aimed at the 
B3 diseases. It acquires scans in a combined, optimized 
approach for optimal biomarker evaluation, allowing an inte-
grated cross-sectional analysis of correlation among the B3 
imaging biomarkers. This can give a clue to what extent the 
(early stages of) B3 diseases are interconnected and which 
factors influence the premature development of one, two or 
three B3 diseases, using the rich database of the Lifelines 
cohort, which can help to identify an ‘at-risk’ subgroup in 
the population.
The ImaLife study has several strengths. First, it is a 
population-based observational study with a large sample 
size. Second, it is a comprehensive radiology study with 
state-of-the-art low-dose CT, standardized scan and evalua-
tion protocols, dedicated software and sophisticated support 
from ICT technicians. Third, the ImaLife study is embed-
ded in the prospective Lifelines cohort study. This allows 
the longitudinal investigation of the relationship between 
imaging biomarkers and clinical progression of the B3 dis-
eases. In addition, the wealth of information in the Lifelines 
database, including environmental factors and microbi-
ome, allows correlation with early imaging biomarkers in 
order to detect new factors influencing the development of 
B3 diseases. Not only conventionally quantitative imaging 
biomarkers are measured, but also new image features are 
extracted (f.e. using radiomics) allowing potentially more 
predictive information from the same CT scan. Also, early 
imaging biomarkers for other degenerative diseases, such 
as liver density for non-alcoholic fatty liver disease, bone 
density or vertebral fractures for osteoporosis, and muscle 
mass can be determined. These imaging biomarkers would 
help in predicting mortality. Lastly, following the ImaLife 
study design, a corollary study, NELCIN-B3, is being set 
up in the Chinese population in collaboration with Chinese 
academic hospitals. This allows the comparison of reference 
values in a Dutch and Chinese population.
Besides the clinical strengths, the ImaLife study will also 
contribute to the development of computer-aided diagno-
sis systems. With the rise of deep learning approaches in 
computer vision, artificial intelligence techniques are widely 
employed in different disciplines to assist domain experts 
in their daily practical work. The development of such a 
system, however, requires not only the implementation of 
the techniques but more importantly the feeding of suffi-
cient amounts of labelled data for the supervised training of 
the system. From this point of view, the collection of scans 
from the ImaLife study and the corresponding evaluation by 
trained readers (including labelling of the data) will be ben-
eficial and necessary for the development of such a system. 
In return, the computer-aided diagnosis system will further 
support the population-based screening study in the sense 
of ruling out normal aging cases, detecting early signs of B3 
diseases and expectantly discovering new biomarkers for the 
diagnosis of certain diseases.
The weaknesses of the study also need to be addressed. 
Firstly, the potential for selection bias. Participants of the 
ImaLife study are recruited from the Lifelines cohort. 
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The Lifelines cohort is a broadly representative sample of 
the general population of the northern Netherlands, how-
ever there is a potential source of selection bias regard-
ing enrollment in the ImaLife study, as participants were 
derived from the (unselected) cohort that underwent lung 
function testing for which there was a number of exclusion 
criteria. Also, individuals below 45 years of age are not 
included, as the expected prevalence of early B3 stages 
and positive imaging biomarkers for lung nodules, COPD 
and CAD are rare below 45 years [24–26]. The participa-
tion rate for ImaLife CT scanning among healthier and 
younger individuals may be higher than the rate in older 
and less healthy individuals, which may lead to bias when 
the reference values of imaging markers derived from 
ImaLife are to be generalized to the larger population. 
Furthermore, the elderly participants who do participate 
in the ImaLife study may be less representative for their 
age groups, because of their robust health status. Addition-
ally, a potentially lower response rate in the elderly may 
result in insufficient power when age-stratified analysis is 
conducted, and the power will be worse for the investiga-
tion of the relationships with rare risk factors. Another 
weakness is that CT scans for lung and for heart are cur-
rently performed as separate acquisitions, which results in 
slightly higher radiation dose. The total study related radi-
ation dose will be between 0.6 and 1.8 mSv for these two 
acquisitions (with an additional 0.1 to 1.3 mSv in a sub-
group undergoing expiratory CT). The risk of long-term 
health effects from radiation dose in this range is either 
too small to be observed or does not exist [45]. However, 
in the future, combined low-dose chest CT might possibly 
be used to gather the B3 imaging biomarkers in one scan. 
This approach needs, however, further validation in order 
to secure accurate imaging biomarker quantification.
Conclusion
The ImaLife study, embedded in the Lifelines cohort, 
is a population-based study in the northern part of the 
Netherlands. Scan data acquisition started at the end of 
August 2017. So far, around 4000 participants have been 
enrolled. The enrollment is expected to be completed in 
the second half of 2020. Participants will be regularly fol-
lowed up according to the Lifelines cohort procedures. The 
ImaLife study will yield reference values of early imaging 
biomarkers for the B3 diseases in the general population, 
and help integration of the B3 imaging biomarkers into 
personalized prevention strategies for healthy ageing.
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